

New analytical method for the determination of pethidine in pharmaceutical formulations and urine samples

Sabry Khalil^{1,2*}, Afaf Bushara^{1,3}

¹Medical Laboratories Department, College of Applied Medical Sciences,
Taif University, Taif 21944, P. O. Box 2425, (KSA)

²Chemistry Department, Faculty of Science, Fayoum University, Fayoum, (EGYPT)

³Department of Chemistry, Faculty of Science, Al Dalanj University, (SUDAN)

E-mail : SabryKhalil1963@gmail.com

ABSTRACT

Ion – associate complexes of pethidine hydrochloride with zinc (II) thiocyanate, potassium ferricyanide and ammonium reineckate were precipitated and the excess unreacted metal complex was determined. A new method was given for the determination of pethidine drug in pure solutions, in pharmaceutical formulations and urine samples using atomic emission and atomic absorption spectrometry. The drug can be determined by the afford method in the range 0.57 - 62.43 $\mu\text{g mL}^{-1}$.

© 2014 Trade Science Inc. - INDIA

KEYWORDS

Atomic emission;
Atomic absorption;
Ion-associate complexes;
Pharmaceutical analysis.

INTRODUCTION

Pethidine;(Pd) is a potent opiate analgesics, which has been employed in the treatment of a variety of medical conditions^[1]. Pethidine hydrochloride; (PdCl) is also used as an illicit drug and therefore it is placed on the substances list drugs that have acceptable medical use and have high potential for abuse in the United States and many other countries. Pethidine is also prescribed as a substitute for heroin^[2], and often used medically as postoperative analgesia. In sports, athletes often take far higher doses of drugs than have been given for therapeutic use or in clinical studies to excel in competition. They have been barred to use by the International Olympic Committee and other sports organizations^[3]. Therefore, determination of pethidine has important practical meanings. To the best of our knowledge few reports have been published on the analysis of pethidine in phar-

maceutical preparations, these methods are sophisticated such as high performance liquid chromatography (HPLC)^[4,5], gas chromatography^[6], gas chromatography in combination with mass spectrometry (GC-MS)^[7,8], spectrophotometry^[9,10], potentiometric analysis^[11-16] and colorimetry^[17]. Many of these methods involve several time-consuming manipulations, extraction steps, derivatization reactions that are liable to various interferences, and are not applicable to colored and turbid solutions either.

Pethidine; (Pd) is a very important pharmaceutical compound. Therefore, we found it important to prepare new ion-associates containing this drug and to study and elucidate their chemical structures. Also the work present a new rapid method for the determination of this drug after transformation into the ion-associates.

Pethidine (Meperidine hydrochloride, Dolantin) (Ethyl, 1-methyl-4-phenylpiperidine-4-carboxylate hy-

Full Paper

drochloride). The chemical structure of pethidine drug is shown in Figure 1.




Figure 1 : Chemical structure of pethidine hydrochloride

The use of simpler, faster, less expensive and sensitive method is desirable.

Although, Inductively Coupled Plasma-Atomic Emission Spectrometry (ICP-AES) and Atomic Absorption Spectrometry (AAS) are rapid methods and have a very low detection limits which can not be reached by most of other methods. The present study includes new ICP-AES and AAS methods for the determination of the investigated drug. The method is based on the precipitating the ion-associates formed as a result of the combination of this drug with an excess of $[\text{Zn}(\text{SCN})_4]^{2-}$, $[\text{Fe}(\text{CN})_6]^{3-}$ and $[\text{Cr}(\text{NH}_3)_2(\text{SCN})_4]^{1-}$. The equilibrium concentration of the metal ion present as the soluble inorganic complex ion in the supernatant solution was determined using atomic emission and absorption.

MATERIALS AND METHODS

Doubly-distilled water and analytical grade reagents were used in the preparation of all solutions. Pethidine was obtained from General Administration of Pharmacy, Ministry of Health (Cairo, Egypt). Demerol tablets containing (50 and 100 mg pethidine hydrochloride / tablet) as Pharmazeutische Produkte Althofstrasse Neuenhof / AG (Switzerland company) were purchased from local market. Zinc sulfate, potassium thiocyanate, potassium ferricyanide and ammonium reineckate were from Aldrich (www.sigmaaldrich.com).

Apparatus

The pH of the solutions was measured using an

Orion Research Model 701A digital pH-meter. Inductively coupled plasma atomic emission measurements were carried out using ICPE- 9000 Shimadzu plasma atomic emission spectrometer and atomic absorption measurements were made on AA-6650 Shimadzu atomic absorption spectrophotometer. Conductimetric measurements were carried out using conductivity measuring bridge type M.C.3 model EBB/10 ($K_{\text{cell}} = 1$); [Chertsey, Surry, England]. The IR absorption spectra were obtained by applying the KBr disk technique using a Pye Unicam SP-300 infrared spectrometer.

Preparation of the standard solutions

Standard solutions of chromium and zinc were prepared by weighing 1.0 g of a high-purity sample (chromium shot and zinc metal, respectively), transferring it to a 1-liter measuring flask and then adding 50 ml of concentrated HNO_3 . After complete dissolution, the solution was filled to the mark with distilled water. The $1000 \mu\text{g mL}^{-1}$ solution was stored in plastic bottles which had been presoaked in dilute HNO_3 . The solutions were stable for approximately one year. Standard solution of iron was obtained from Aldrich

Emission and absorption measurements

Analytical Parameters for the Measurement of Cr, Zn and Fe Using ICP-AES are listed in TABLE 1. Using AAS the Zn (II) was measured at wavelength 213.9 nm, slit 0.7 nm, relative noise 1.0, sensitivity $0.018 \mu\text{g mL}^{-1}$ and linear range $1.0 \mu\text{g mL}^{-1}$. The instruments were equally adequate for present purposes and were used according to availability. The atomic spectrometry was calibrated as in the previously reported work^[18-20].

Determination of solubility of the Ion – associates

The solid ion-associate was added in excess to a solution of the optimum pH and ionic strength. The solution was shaken for 4-6 h and left to stand for a weak to attain equilibrium. Then the saturated solution was filtered into a dry beaker (rejecting the first few ml of filtrate). The equilibrium concentration of the metal ion present in the form of a soluble inorganic complex was measured using atomic spectrometry. Hence, the solubility (S) of the precipitate was evaluated, from which the solubility product of the ion-associate was calculated.

TABLE 1 : Analytical Parameters for the Emission Measurement of Cr, Zn and Fe Using ICP-AES

Element	Wavelength		Plasma position	DL (mg/L)	LDR (mg/L)	BEC (mg)	RSD x BEC (%)
	(nm)	Order					
Cr	267.71	84	0	0.01	0.1-1000	0.4	7 x 0.7
Zn	206.20	109	0	0.01	0.1-1000	0.3	10 x 0.9
Fe	248.30	90	0	0.01	0.1-1000	0.2	1 x 0.7

Note. DL, detection limit; LDR, linear dynamic range; BEC, background equivalent concentration; RSD, relative standard deviation. For all elements: state, ion; entrance slits, 50 x 300 μm ; exit slits, 100 x 300 μm .

Conductometric measurements

The stoichiometry of the ion-associates was elucidated also by conductometric titrations^[21] of the drugs with $[\text{Zn}(\text{SCN})_4]^{2-}$, $[\text{Fe}(\text{CN})_6]^{3-}$ and $[\text{Cr}(\text{NH}_3)_2(\text{SCN})_4]^{1-}$ solutions.

Analytical determination of pethidine in aqueous solutions

Aliquots (0.05 - 5.5 mL) of 0.001 mol L⁻¹ drug solutions were quantitatively transferred to 25 mL volumetric flasks. To each flask 1.0 mL of 0.01 mol L⁻¹ standard solution of $[\text{Zn}(\text{SCN})_4]^{2-}$, $[\text{Fe}(\text{CN})_6]^{3-}$ and $[\text{Cr}(\text{NH}_3)_2(\text{SCN})_4]^{1-}$ was added and the volume was completed to the mark with the aqueous solutions of the optimum pH and ionic strength (prepared from HCl and NaOH). The solutions were shaken well and left to stand for 15 min then filtered through Whatman P/S paper (12.5 cm). The equilibrium metal ion concentration in the filtrate was determined using ICP-AES or AAS. The consumed metal ion (Cr, Fe or Zn) in the formation of ion-associates was calculated, and the drug concentration was determined indirectly.

Analytical determination of pethidine in pharmaceutical preparations and urine samples

The Pethidine - containing pharmaceutical preparations (Demerol 50 and 100 mg tablets) were successfully assayed using the present method. Sampling were made by grinding (20 and 10 tablets), respec-

tively then taking 0.65 - 60.25 and 1.25 - 58.45 μg / ml of Demerol 50 and 100 mg tablets, respectively. Urine samples were obtained from 20 patients after 2 - 8 hours of taking dose. In all cases the tablets and urine samples were analyzed at the optimum condition solution applying the above described procedure.

RESULTS AND DISCUSSION

The results of elemental analysis (TABLE 2) of the produced solid ion associates reveal that two pethidinium cations form ion associates with one $[\text{Zn}(\text{SCN})_4]^{2-}$ and three $[\text{Fe}(\text{CN})_6]^{3-}$, while only one pethidinium cation combines with $[\text{Cr}(\text{NH}_3)_2(\text{SCN})_4]^{1-}$ to form a 1:1 ion associate. These results are comparable to the previously reported results^[22-24].

Conductometric titrations of the investigated inorganic complexes with Pd HCl were performed to give insight into the stoichiometric compositions of the ion-associates formed in solutions. In case of ion associates with $[\text{Zn}(\text{SCN})_4]^{2-}$, the characteristic curves break at a molecular ratio ($[\text{Pd}] / [\text{x}]^{n-}$) of about 2, confirming the formation of 2:1 (Pd : x²⁻) ion associates but in the case of the reineckate anion where the curve exhibits a sharp break at the 1:1 molecular ratio and in the case of $[\text{Fe}(\text{CN})_6]^{3-}$ anion the curve exhibits a sharp break at the 3:1 molecular ratio. The results obtained coincide with the elemental analysis of the precipitated ion-associates.

TABLE 2 : Elemental analysis, composition and some physical properties of pethidine ion - associates

Drug	Ion-associate composition	m. p. °C	Molar ratio	Color	% Found (calculated)			Metal (Zn, Cr or Fe)
					C	H	N	
Pethidine	$(\text{C}_{15} \text{H}_{21} \text{NO}_2)_2 [\text{Zn} (\text{SCN})_4]$	285	2 : 1	white	56.11 (56.15)	5.73 (5.78)	11.51 (11.56)	8.94 (8.99)
	$(\text{C}_{15} \text{H}_{21} \text{NO}_2) [\text{Cr} (\text{NH}_3)_2 (\text{SCN})_4]$	344	1 : 1	pink	40.26 (40.33)	4.73 (4.78)	17.29 (17.34)	9.15 (9.20)
	$(\text{C}_{15} \text{H}_{21} \text{NO}_2)_3 [\text{Fe} (\text{CN})_6]$	273	3 : 1	white	64.09 (64.16)	6.56 (6.60)	13.18 (13.21)	5.84 (5.87)

Full Paper

The optimum pH and ionic strength values (TABLE 3) have been elucidated by determining the solubility of the ion-associates in HCl-NaOH solutions of different pH values and ionic strengths. The best were those exhibiting lowest solubility values.

TABLE 3 : Solubility and solubility product of pethidine ion-associates at their optimum conditions of pH and ionic strength (μ) values at 25° C

Pd- Ion – associate	pH	μ	p ^s	p _{sp} ^k
(C ₁₅ H ₂₁ NO ₂) [Cr (NH ₃) ₂ (SCN) ₄]	5.0	0.7	9.45	18.90
(C ₁₅ H ₂₁ NO ₂) ₂ [Zn (SCN) ₄]	4.0	0.4	7.12	20.75
(C ₁₅ H ₂₁ NO ₂) ₃ [Fe(CN) ₆]	3.0	0.6	8.26	31.61

p^s : -log solubility; p^ksp : -log solubility product

TABLE 4 : Determination of Pethidine in aqueous solutions, pharmaceutical preparations and urine samples by ICP-AES and AAS

Sample	Amount taken (μ g)	Mean recovery (%)	Mean RSD (%)
Using [Zn (SCN)₄]^{2-*}			
Pure Pd solution	0.57 - 62.43	99.92	0.7
Demerol tablets ^a (50 mg Pd / tablet)	0.65 - 60.25	99.93	0.5
Demerol tablets ^a (100 mg Pd / tablet)	1.25 - 58.45	99.93	0.6
Urine after 2 hs	5.75 - 45.25	99.94	0.7
Urine after 6 hs	9.45 - 35.35	99.93	0.6
Urine after 8 hs	15.25 - 25.15	99.95	0.5
Using [Zn(SCN)₄]^{2-**}			
Pure Pd solution	0.57 - 62.43	99.96	0.6
Demerol tablets ^a (50 mg Pd / tablet)	0.65 - 60.25	99.95	0.7
Demerol tablets ^a (100 mg Pd / tablet)	1.25 - 58.45	99.96	0.7
Urine after 2 hs	5.75 - 45.25	99.95	0.8
Urine after 6 hs	9.45 - 35.35	99.95	0.9
Urine after 8 hs	15.25 - 25.15	99.94	0.6
Using [Cr (NH₃)₂ (SCN)₄]^{1-*}			
Pure Pd solution	0.57 - 62.43	100.01	0.6
Demerol tablets ^a (50 mg Pd / tablet)	0.65 - 60.25	100.03	0.5
Demerol tablets ^a (100 mg Pd / tablet)	1.25 - 58.45	100.03	0.7
Urine after 2 hs	5.75 - 45.25	100.07	0.6
Urine after 6 hs	9.45 - 35.35	100.05	0.7
Urine after 8 hs	15.25 - 25.15	100.02	0.8
Using [Fe(CN)₆]^{3-*}			
Pure Pd solution	0.57 - 62.43	98.95	0.7
Demerol tablets ^a (50 mg Pd / tablet)	0.65 - 60.25	98.96	0.8
Demerol tablets ^a (100 mg Pd / tablet)	1.25 - 58.45	98.94	0.9
Urine after 2 hs	5.75 - 45.25	98.93	0.7
Urine after 6 hs	9.45 - 35.35	98.92	0.8
Urine after 8 hs	15.25 - 25.15	98.97	0.6

RSD : Relative Standard Deviation (five determinations); * By ICP-AES; ** By AAS; ^a Althofstrasse Neuenhof / AG (Switzerland company)

of pethidine using $[\text{Zn}(\text{SCN})_4]^{2-}$, $[\text{Fe}(\text{CN})_6]^{3-}$ and $[\text{Cr}(\text{NH}_3)_2(\text{SCN})_4]^{1-}$ was determined, respectively, which means that this method is applicable over a wider concentration range than that of the previously published colorimetric method¹⁷ in which pethidine was determined in the ranges 5 – 45 $\mu\text{g mL}^{-1}$.

In pharmaceutical analysis it is important to test the selectivity toward the excipients and the fillers added to the pharmaceutical preparations. Fortunately, such materials mostly do not interfere. It is clear from the results obtained for the pharmaceutical preparations (TABLE 4) that these excipients do not interfere.

In order to establish whether the proposed method exhibits any fixed or proportional bias, a simple linear regression^[25] of observed drug concentration against the theoretical values (five points) was calculated. The student's *t-test*^[25] (at 95% confidence level) was applied to the slope of the regression line which showed that it did not differ significantly from the ideal value of unity. Hence, it can be concluded that there are no systematic differences between the determination and the true concentration over a wide range. The standard deviations (SD) can be considered satisfactory at least for the level of concentrations examined.

CONCLUSION

The present method is as good as those reported before where, 0.57 - 62.43 $\mu\text{g mL}^{-1}$ solution of pethidine using $[\text{Zn}(\text{SCN})_4]^{2-}$, $[\text{Fe}(\text{CN})_6]^{3-}$ and $[\text{Cr}(\text{NH}_3)_2(\text{SCN})_4]^{1-}$ were determined, respectively, which means that this method is applicable over a wider concentration range than previously published method¹⁷ in which pethidine was determined in the ranges 5 – 45 $\mu\text{g mL}^{-1}$.

Although the present method is more time consuming than some other methods, it exhibits fair sensitivity and accuracy. Moreover, the reproducibility of the results is superior to those obtained with other methods.

ACKNOWLEDGEMENTS

The Authors wish to thank College of Applied Medical Sciences - Taif University for supporting this work.

REFERENCES

- [1] S.White, S.H.Y.Wong; Guidelines for Therapeutic Drug Monitoring Services, In: A.Warner, T.Annesley, (Eds); The National Academy of Clinical Biochemistry, Washington, 63-73 (1999).
- [2] P.A.Greenwood, C.Merrin, T.Mc Creedy, G.M.Greenway; Chemiluminescence μTAS for the Determination of Atropine and Pethidine, *Talanta*, **56(3)**, 539-545 (2002).
- [3] Han, Y.Du, E.Wang; Simultaneous Determination of Pethidine and Methadone by Capillary Electrophoresis with Electrochemiluminescence Detection of Tris (2,2'-bipyridyl) ruthenium (II), *Microchemical Journal*, **89(2)**, 137-141 (2008).
- [4] T.G.Venkateshwaran, J.T.Stewart, D.T.King; HPLC Determination of Morphine - Ondansetron and Meperidine-Ondansetron Mixture in 0.9% Sodium Chloride Injection, *Journal of Liquid Chromatography & Related Technologies*, **19(8)**, 1329-1338 (1996).
- [5] C.R.Meatherall, D.R.P.Guay, R.P.Dvid; Analysis of Meperidine and Normeperidine in Serum and Urine by High-Performance Liquid Chromatography, *Journal of Liquid Chromatography*, **338**, 141-149 (1985).
- [6] S.W.Myung, S.Kim, J.H.Park, M.Kim, J.C.Lee, T.J.Kim; Solid-Phase Microextraction for the Determination of Pethidine and Methadone in Human Urine Using Gas Chromatography with Nitrogen-Phosphorus Detection, *Analyst*, **124(9)**, 1283-1286 (1999).
- [7] Liu, X.Y.Hu, Y.Luo; Investigation of Meperidine and Its Metabolites in Urine of an Addict by Gas Chromatography-Flameionization Detection and Gas Chromatography-Mass Spectrometry, *Journal of Chromatography B: Biomedical Sciences and Applications*, **658**, 375-379 (1994).
- [8] A.Ishii, M.Tanaka, R.Kurihara, K.Watanabe-Suzuki, T.Kumazawa, H.Seno, O.Suzuki, Y.Katsumata; Sensitive Determination of Pethidine in Body Fluids by Gas Chromatography-Tandem Mass Spectrometry, *Journal of Chromatography B*, **792**, 117-121 (2003).
- [9] H.Farsam, M.R.Nadjari-Moghaddam; Spectrophotometric Determination of Meperidine Hydrochloride in Pharmaceutical Preparations by Complexation with Bromocresol Green, *Journal of Pharmaceutical and Biomedical Analysis*, **2**, 543-547 (1984).
- [10] W.Jin, Y.We; Spectrophotometric determination of

Full Paper

- pethidine hydrochloride preparation using iodide, Chinese j. of Modern Applied Pharmacy, **17**, 25-33 (2013).
- [11] A. Shalaby, M. El-Tohamy, M. El-Maamly, H. Y. Aboul-Enein; Potentiometric Membrane Sensor for the Selective Determination of Pethidine in Pharmaceutical Preparations and Biological Fluids, *Annali di Chimica*, **97(10)**, 1065-1074 (2007).
- [12] Z.H. Liu, M.L. Wen, J. Xiong; A Pethidine Selective Polymeric Membrane Electrode Based on Pethidine- Silicotungstate, *Analytical Sciences*, **16(8)**, 885-887 (2000).
- [13] Z.H. Liu, M.L. Wen, J. Xiong; Plastic Membrane Electrode for the Potentiometric Determination of Pethidine Hydrochloride in Pharmaceutical Preparations, *Fresenius Journal of Analytical Chemistry*, **368(4)**, 335-337 (2000).
- [14] Z.H. Liu, M.L. Wen, Y. Yao, J. Xiong; Plastic Pethidine Hydrochloride Membrane Sensor and Its Pharmaceutical Applications, *Sensors and Actuators B*, **72**, 219-223 (2001).
- [15] Z.H. Liu, M.L. Wen, Y. Yao, J. Xiong; A Pethidine Selective Polymeric Membrane Electrode, *Boletín de la Sociedad Chilena de Química*, **47(2)**, 163-168 (2002).
- [16] H.M. Abu-Shawish, N. Abu Ghalwa, G.I. Khraish, J. Hammad; A New Potentiometric sensor for determination of pethidine hydrochloride in ampoules and urine, *American J. of Analytical Chemistry*, **2**, 56-65 (2011).
- [17] R. Gridhar, S. Menon, Y.K. Agrawal; Colorimetric determination of meperidine in pharmaceutical preparations, *Int. J. Pharm. Sciences*, **49(1)**, 32-33 (1987).
- [18] S. Khalil, N. Shalaby; Microdetermination of Sildenafil, tadalafil and vardenafil in pharmaceutical formulations and urine samples, *Inter. J. Pharm. Bio Sci.*, **4(1)**, 1037-1046 (2013).
- [19] S. Khalil, S.S. Al-Zahrani, Y.M. Hussein, A.I. Turkistani; Analytical Applications of Atomic Emission Spectrometry for the microdetermination of Sildenafil, tadalafil and vardenafil drugs, *Analytical Chemistry: An Indian Journal*, **14(6)**, 201-207 (2014).
- [20] S. Khalil; Applications of ion-associates for the microdetermination of vardenafil drugs using atomic emission spectrometry, *Mikrochemica Acta*, **130**, 181-185 (1999).
- [21] J.J. Lingantes; *Electroanalytical Chemistry*, 2 nd. Edition, Interscience, New York, 90 (1958).
- [22] S. Khalil, A. Kelzieh; Determination of verapamil in pharmaceutical formulations using atomic emission spectrometry, *J. Pharm. Biomed. Anal.*, **27**, 123 (2002).
- [23] S. Khalil, S.A. Ibrahim, F.I. Zedan, M.S. AbdEl-Monem; AAS determination of bromhexine, flunarizine and ranitidine hydrochlorides in pharmaceutical formulations, *Chem. Anal.*, **50**, 897-905 (2005).
- [24] S. Khalil, M.M. El-Rabiehi; Indirect atomic absorption spectrometric determination of pindolol, propranolol and levamisole hydrochlorides based on formation of ion associates with manganese thiocyanate and potassium ferricyanide, *J. Pharm. Biomed. Anal.*, **22**, 7-14 (2000).
- [25] J.C. Miller, J.N. Miller; *Statistics for Analytical Chemistry*, Ellis Horwood, Chichester, 90 (1984), 2nd Edition, Ellis Horwood, 185 (1988).